Skip to content

HEW PHARMA

Active Private limited companyfounded 2017active for 9 yearsHeiken 5, 2920 KalmthoutKBO/BCE: BE 0681.590.393 subsidiary of

Lifetime

8 annual accounts with figures on one time axis
peak of €690,454 in 2020
€129,937▲ 340%
lowest -€240,667 in 2019
€30,396▲ €117,686
peak of €336,072 in 2023
€279,177▲ 12.2%
€726,882▼ 1.8%
peak of 5.3 FTE in 2020
-not published
Board3 names since 2017
3 directors and 2 others
Owners2 names in the annual accounts
60% and 1 other
Documentsfilings and deeds
30-09-202661 days late
2025micro format
Gross margin from €29,521 to €129,937Profit of €30,396, after a lossEquity from €248,782 to €279,177

Key points

from the 2025 annual accounts

Result

€30,396 €30,396
-€87,3002024€30,4002025

Back in profit in 2025, after a loss of €87,290 in 2024.

Turnover

≈ €320,000 estimated

The accounts state no turnover.

Debts

€726,882 72% of the balance sheet
Financial debts 12%Suppliers 64%Taxes and wages 9%Other 15%

Of this, €636,882 falls due within a year.

Investments

€41,162 1.5 times depreciation
2021202220232025

Green is investment, beige is depreciation. Machinery stands 21.0% higher than in 2024.

Staff

1.3 FTE from 5.3 in 2020

Between 2020 and 2025, the number of full-time equivalents fell by 75%.

Filings

8 annual accounts 61 days
AprilJune31 JulyOctober20202025

Latest accounts filed late: after the legal deadline.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,272 companies had the same profile as HEW PHARMA has now. Each dot stands for 9 companies, two years later.

94.6%
were still trading
2.6%
stopped another way
2.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,272 companies, not a prediction for HEW PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager, since 19-09-2017
Manager, , since 19-09-2017
Director, since 14-02-2022
  • 60%score equity €1.8m (2025) · annual accounts 30-06-2025 of
  • 20%score equity €573.3m (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0681590393
appointed as director Gazette deed
1 director resigning · and act as permanent representatives · General meeting of 14-10-2019 · Gazette deed
Incorporation Founded by · Founded by · Founded by · Gazette deed
All 20 events

Comparable companies

same main activity, similar in size and age
Company
HEW PHARMA Kalmthout €1.0m €129,937 27.7% -
OLYS Pharma La Hulpe €1.0m €158,424 56.0% -
Pharmentum Kontich €1.2m €40,883 25.9% 1
272BIO Ghent €0.7m €104,252 -31.8% 5.2
INTIBIO Bree €0.4m €278,015 35.8% -
LBS Ghent €0.3m €99,629 20.8% -
Dierenartsen Hond en Kat Deinze €0.3m €80,014 0.7% -

These companies have the same main activity as HEW PHARMA: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €292,000 and €1.2m, founded between 2014 and 2021.

Official details

Source: KBO
Status
Active since 20-09-2017Normal situation
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 5 others
Joint committee
207White-collar workers in the chemical industry · annual accounts 2025
Establishment unit
2.269.640.4442920 Kalmthout, since 20-09-2017
Financial year end
31 December
Peppol
Reachable since 02-01-2026
Company details

Annual accounts 2025

€1.0m▲ 1.7%
Employeeson 31-12-2025
1▼ 50.0%
Filing
Filed on 30-09-2026
Financials

Insights on HEW PHARMA

HEW PHARMA files the micro format. That format states no turnover. The gross margin rose from -€20,651 in 2018 to €129,937 in 2025.

holds 60% of the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about HEW PHARMA

What is the company number of HEW PHARMA?
The company number of HEW PHARMA is 0681.590.393. The VAT number is the same number with BE in front: BE 0681.590.393.
Where is HEW PHARMA based?
The registered office is at Heiken 5, 2920 Kalmthout.Company details
What does HEW PHARMA do?
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
What is the legal form of HEW PHARMA?
HEW PHARMA is a private limited company (BV).
When was HEW PHARMA founded?
HEW PHARMA was founded on 20-09-2017.
Is HEW PHARMA still active?
Yes, HEW PHARMA is an active enterprise in the KBO register.
How many employees does HEW PHARMA have?
HEW PHARMA had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does HEW PHARMA fall under?
In its 2025 annual accounts, HEW PHARMA states joint committee 207 (White-collar workers in the chemical industry).
What is the turnover of HEW PHARMA?
The turnover in financial year 2025 is about €320,000. This figure is estimated from the gross margin of €129,937 and 2,451 comparable companies of the same size. It probably lies between €210,000 and €500,000. It is a rough estimate.
Is HEW PHARMA profitable?
In financial year 2025, HEW PHARMA made a profit of €30,396.
Where can I find the annual accounts of HEW PHARMA?
HEW PHARMA filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of HEW PHARMA due?
HEW PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.